Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy.

OBJECTIVE To determine what proportion of patients with acute myocardial infarction are not eligible for thrombolytic therapy and to assess their natural history. DESIGN Retrospective chart review. SETTING A large community-based hospital. PATIENTS All patients with acute myocardial infarction hospitalized during a 27-month period. MEASUREMENTS Of 1471 patients with acute myocardial infarction, 230 (16%) received thrombolytic therapy according to the protocol and an additional 97 (7%) received nonprotocol thrombolytic therapy, primary coronary balloon angioplasty, or both because of contraindications. The other 1144 patients (78%) did not receive reperfusion therapy. MAIN RESULTS The patients who did not receive thrombolytic therapy were older, more likely to be women, and more likely to have a history of hypertension, previous myocardial infarction, or chronic angina (all comparisons, P less than 0.002). An average of 1.9 reasons for exclusion were identified per patient among the ineligible patients. Mortality was fivefold higher among ineligible patients (19%; Cl, 16% to 21%) than among protocol-treated patients (4%; Cl, 1% to 6%) (P less than 0.001). In-hospital mortality rates for excluded patients were 28% (Cl, 23% to 32%) in elderly patients (age, greater than 76 years; n = 396); 29% (Cl, 23% to 35%) in patients with stroke or bleeding risk (n = 209); 17% (Cl, 14% to 20%) in patients with delayed presentation (greater than 4 hours after the onset of chest pain; [n = 599]); 14% (Cl, 11% to 16%) in patients with an ineligible electrocardiogram (ECG) (n = 673); and 26% (Cl, 21% to 32%) in patients with a miscellaneous reason for exclusion (n = 243). Independent predictors of increased mortality were: age greater than 76 years, stroke or other bleeding risk, ineligible ECG, or the presence of two or more exclusion criteria. CONCLUSIONS Thrombolytic therapy is currently used in the United States for only a minority of patients with acute myocardial infarction: those who have low-risk prognostic characteristics.

[1]  E. Topol,et al.  Selection of patients with acute myocardial infarction for thrombolytic therapy. , 1990, Annals of internal medicine.

[2]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico. MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.

[3]  C. Grines,et al.  Optimal utilization of thrombolytic therapy for acute myocardial infarction: concepts and controversies. , 1990, Journal of the American College of Cardiology.

[4]  A. DeMaria,et al.  Mechanism of acute myocardial infarction in patients with prior coronary artery bypass grafting and therapeutic implications. , 1990, The American journal of cardiology.

[5]  B. Chaitman,et al.  The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from thrombolysis in myocardial infarction Phase I, open label studies and the Thrombolysis in Myocardial Infarction Phase II pilot study. The TIMI Investigators. , 1989, Journal of the American College of Cardiology.

[6]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[7]  R. Califf,et al.  Adoption of thrombolytic therapy in the management of acute myocardial infarction. , 1988, The American journal of cardiology.

[8]  H. Lambertz,et al.  THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.

[9]  E. Topol,et al.  Reperfusion therapy of acute myocardial infarction. , 1988, Progress in cardiovascular diseases.

[10]  E. Michelson,et al.  Thrombolytic therapy of acute myocardial infarction: emerging challenges of implementation. , 1987, Journal of the American College of Cardiology.

[11]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[12]  R. Balcon,et al.  What proportion of patients with myocardial infarction are suitable for thrombolysis? , 1987, British heart journal.

[13]  W. Littler,et al.  ELIGIBILITY FOR THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION , 1987, The Lancet.

[14]  P. Shah,et al.  Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase. , 1987, The American journal of cardiology.

[15]  G. Timmis,et al.  Hemorrhage vs rethrombosis after thrombolysis for acute myocardial infarction. , 1986, Archives of internal medicine.

[16]  B. Pitt,et al.  A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. , 1986, The New England journal of medicine.

[17]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico. EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[18]  J. Parker,et al.  Nitroglycerin lingual spray: clinical efficacy and dose-response relation. , 1986, The American journal of cardiology.

[19]  G. Timmis,et al.  The influence of infarction site and size on the ventricular response to coronary thrombolysis. , 1985, Archives of internal medicine.

[20]  J. W. Kennedy,et al.  Acute myocardial infarction treated with intracoronary streptokinase: a report of the Society for Cardiac Angiography. , 1985, The American journal of cardiology.

[21]  G. Timmis,et al.  Hemorrhage and the products of fibrinogen digestion after intracoronary administration of streptokinase. , 1984, Circulation.

[22]  G. Timmis,et al.  Intracoronary streptokinase in clinical practice. , 1982, American heart journal.